Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-cluster of differentiation 19 (CD-19) fully humanized antibody or antibody fragment and chimeric antigen receptor comprising same and application of fully humanized antibody or antibody fragment

A technology of chimeric antigen receptor and fully human antibody, which is applied in anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, receptor/cell surface antigen/cell surface determinant, application, etc., can Solve the problems of poor prognosis and high recurrence rate

Active Publication Date: 2020-06-19
CHANGZHOU VELOX PHARMA SCI & TECH CO LTD
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] B-cell malignancies are common hematological malignancies. Although the first-line clinical treatment has a certain effect, the recurrence rate is high and the prognosis is poor. CD19, as a molecular target for immunotherapy of B-cell malignancies, has received great attention

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-cluster of differentiation 19 (CD-19) fully humanized antibody or antibody fragment and chimeric antigen receptor comprising same and application of fully humanized antibody or antibody fragment
  • Anti-cluster of differentiation 19 (CD-19) fully humanized antibody or antibody fragment and chimeric antigen receptor comprising same and application of fully humanized antibody or antibody fragment
  • Anti-cluster of differentiation 19 (CD-19) fully humanized antibody or antibody fragment and chimeric antigen receptor comprising same and application of fully humanized antibody or antibody fragment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0083] 1. Construction of directional anti-CD19 fully human antibody sub-library

[0084] 1.1 Using phage display technology, the anti-human CD19 specific antibody sub-library was screened based on the fully human natural antibody library independently constructed by Fellowes.

[0085] (1) Establish a phage antibody library of fully human single-chain antibodies:

[0086] Design primers to amplify the heavy chain variable region and light chain variable region of the antibody, connect the heavy chain variable region and light chain variable region with Linker by overlapping extension PCR, and obtain the full-length PCR product, use SfiI Digest the PCR product and the pCGMT3 phagemid vector, electrotransform the ligated transformation product into XL1-blue competent cells, then add 3 mL of SOC medium to the competent cells, incubate at 30°C for 1 hour, add a final concentration of 50 μg / mL of ampicillin, 20 mL of 10 μg / mL tetracycline solution, and shake at 37°C for 2 hours. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an anti-cluster of differentiation 19 (CD-19) fully humanized antibody or antibody fragment and a chimeric antigen receptor comprising the same and application of the fully humanized antibody or antibody fragment. The antibody or antibody fragment or a nucleic acid coding the antibody or antibody fragment can be used for preparing host cells, lentiviral plasmids, tumor diagnosis drugs, targeted anti-tumor drugs and the like. The antibody or antibody fragment disclosed by the invention can be bound to humanized CD19 protein by high specificity.

Description

[0001] The present invention is a divisional application, the original application number is "201911234429.6", the original application date is December 5, 2019, and the title of the invention is "a fully human antibody or antibody fragment against CD19, a chimeric antigen receptor and its application". technical field [0002] The invention relates to the technical field of biomedicine, in particular to a fully human antibody or antibody fragment of anti-CD19 and its chimeric antigen receptor and application. Background technique [0003] B-cell malignancies are common hematological malignancies. Although the first-line clinical treatment has certain curative effect, the recurrence rate is high and the prognosis is poor. As a molecular target for immunotherapy of B-cell malignancies, CD19 has received great attention. CD19 is a specific surface protein of normal and malignant B lymphocytes, which plays an important role in the development, proliferation and differentiation o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C07K19/00C12N5/10C12N15/867A61K39/00A61P35/00
CPCC07K16/2803C07K14/7051A61K39/0011A61P35/00C07K2319/02C07K2319/03C07K2319/33C07K2317/622C12N2740/15043
Inventor 杨光
Owner CHANGZHOU VELOX PHARMA SCI & TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com